The review found no eligible studies for this question.
Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).
Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).
Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).
Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).
Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).
Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).
Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).
Early (less than seven days following birth) higher showed no clear difference in mortality (latest time reported up to hospital discharge) compared with lower sodium intake (low certainty).
Late (seven days or more following birth) higher may leads to lower hyponatraemia (< 130 mmol/L) compared with lower sodium intake (low certainty).
It is very uncertain whether late (seven days or more following birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).
Late (seven days or more following birth) higher may leads to lower postnatal growth failure (weight < 10th percentile) compared with lower sodium intake (low certainty).
It is very uncertain whether late (seven days or more following birth) higher changes necrotising enterocolitis compared with lower sodium intake (very low certainty).